We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Bone Loss After Liver Transplant

By HospiMedica staff writers
Posted on 19 Aug 2005
A drug used to treat osteoporosis, when used in combination with calcium and vitamin D, can prevent the additional bone loss that commonly occurs after liver transplants, according to a study appearing in the August 2005 issue of Liver Transplantation.

Osteoporosis often occurs in patients with end-stage liver disease and can be worsened by the immunosuppressive drugs given to prevent rejection following transplantation. More...
Researchers assessed osteoporosis in 136 pre-liver-transplant patients between January 1999 and December 2003 at Innsbruck Medical University (Austria). All patients on the list were given 1,000 mg of calcium and 400 IE of vitamin D daily. In addition, bisphosphonate (alendronate) was given following liver transplant to those patients who had either osteopenia or osteoporosis. Patients whose bone mineral density (BMD) decreased following transplant were also given biophosphonate.

"The striking result of this study was that alendronate combined with calcium and vitamin D almost completely prevented further bone loss in the first four months after liver transplant,” observed the researchers, led by Gunda Millonig of the department of gastroenterology and hepatology at Innsbruck Medical University. "This is a significant improvement compared to the natural course of bone loss within the first few months after liver transplant.”

In addition, patients with osteopenia and osteoporosis, who accounted for 72% of the patients in the study, remained stable on the alendronate therapy for the first four months after transplant and showed improved BMD over the next three years, although their BMD never reached normal levels. The researchers conclude that while the results were promising, further randomized studies are needed.




Related Links:
U. of Innsbruck

New
Gold Member
Handheld Blood Glucose Analyzer
STAT-Site
Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
New
Medical Adhesive
MED 5570U
New
Pediatric Mask
Respire SOFT
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Health IT

view channel
Photo courtesy of Adobe Stock

Automated System Classifies and Tracks Cardiogenic Shock Across Hospital Settings

Cardiogenic shock remains a difficult, time-sensitive emergency, with delayed identification driving poor outcomes and persistently high mortality. Many cases go undocumented even at advanced stages, hindering... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.